Ophthotech Corp Receives a Buy from Chardan Capital

Chardan Capital analyst Gbola Amusa MD CFA maintained a Buy rating on Ophthotech Corp (NASDAQ: OPHT) today and set a price target of $125. The company’s shares closed last Friday at $43.75.

Ophthotech Corp has an analyst consensus of Moderate Buy, with a price target consensus of $81.25.

The company has a one year high of $72.51 and a one year low of $36.46. Currently, Ophthotech Corp has an average volume of 421.4k.

Financial bloggers on sites such as zacks.com, investorplace.com and others, seem to have a Positive view on OPHT. When evaluating the opinions of financial bloggers over the last 3 months, 75% of bloggers have indicated a Bullish sentiment, while 25% have indicated a Bearish sentiment. The average blogger Bullish sentiment in the Healthcare sector is 75% which is equal to the blogger sentiment of OPHT.

Like Chardan Capital`s latest rating, based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPHT in relation to earlier this year. Last month, David Guyer, a the Chief Executive Officer of OPHT bought 29,910 shares for a total of $299,997.

According to TipRanks.com, CFA is a 4-star analyst with an average return of 9.1% and a 55.7% success rate. CFA covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Immune Pharmaceuticals, and Lion Biotechnologies.

Ophthotech Corp is a biopharmaceutical company. The Company is engaged in the development of novel therapeutics to treat diseases of the back of the eye, developing therapeutics for age-related macular degeneration.